News blog

Proximagen Neuroscience

  • BY: Andrew Hore |
  • POSTED: 29/08/2007 |

Proximagen, which focuses on the discovery of treatments for neurodegenerative diseases, says pre-clinical studies of its Parkinson’s disease treatment are encouraging. 

Proximagen has tested a number of compounds for its PRX1 treatment for Parkinson’s disease. It appears to have found at least one that is more effective than L-DOPA, which is the best treatment currently available. It is more consistent and involuntary movements are no worse. 

The PRX4 neuroprotection treatment has received funding from the Michael J Fox Foundation and Elan Corporation has an option for worldwide commercial licensing rights. It involves a neuroprotective gene that delivers genetic material directly into brain cells.

There is £10.4m of cash in the bank so the company has enough funding for its immediate needs. The cash outflow was £1.2m in the first six months of 2007.

Proximagen announced that it had received approaches from potential bidders at the end of July. There is no further news about this.

© 2018 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds